Sun Pharmaceutical Industries Ltd on Friday reported a 36.2 percent year-on-year decline in consolidated net profit to Rs 1,989 crore for the quarter ended September 2026 (Q2 FY27), due to exceptional charges related to its proposed acquisition of Organon & Co and a settlement in a US antitrust litigation case.
The pharmaceutical company's consolidated revenue from operations rose 11.9 percent year-on-year to Rs 16,198.7 crore during the July-September quarter, supported by growth in its India and emerging markets businesses, even as US formulation sales declined.
Sun Pharma's adjusted net profit stood at Rs 3,162 crore, up 1.4 percent year-on-year, compared with Rs 3,118 crore in the corresponding quarter last year.
Its earnings before interest, tax, depreciation and amortisation (EBITDA) increased 4.8 percent year-on-year to Rs 4,743.9 crore, with an EBITDA margin of 29.3 percent. Profit before exceptional items and tax rose 6.3 percent to Rs 4,428.2 crore.
Sun Pharma stock jumped and was trading at Rs 1,835 on NSE in the afternoon session, up 4.2 percent from the previous close. The shares are up 4.4 percent year-to-date, outperforming Nifty 50, which has fallen 11.9 percent in the same period.